RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?
RADical response puts an exceptional responder in CHKmate: a synthetic lethal curative response to DNA-damaging chemotherapy?
复制标题
RADical 反应使 CHKmate 成为一种特殊的反应者：对 DNA 损伤化疗的合成致死治疗反应？
DOI：
10.1158/2159-8290.cd-14-0738
复制
发表时间：
2014
期刊：
影响因子：
28.2
通讯作者：
Mills,GordonB
中科院分区：
文献类型：
--
作者：
Peng,Guang;Woodman,ScottE;Mills,GordonB
摘要：在本期《癌症发现》杂志上，AI-Ahmadie及其同事发现，RAD50基因的体细胞突变可能是导致对复发、转移性小细胞癌患者使用DNA损伤剂伊立替康和检查点激酶1抑制剂进行全身联合治疗后出现不寻常疗效的一个可能因素。这项研究强调了在早期临床试验中深入分析对化疗和靶向治疗的特殊应答者的重要性，并为开发基于癌症基因组的联合疗法开辟了新的途径，以通过合成致命相互作用来提高传统化疗的疗效。©2014 AACR.参见AI-Ahmadie等人的相关文章，第1014页
Summary:In this issue ofCancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in theRAD50gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome–based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.Cancer Discov; 4(9); 988–90. ©2014 AACR.See related article by AI-Ahmadie et al., p. 1014
影响因子：
16
作者：
Ciccia A;Elledge SJ
通讯作者：
Elledge SJ
在依维莫司和pazopanib的I期试验中激活患者的MTOR突变。
影响因子：
28.2
作者：
Wagle N;Grabiner BC;Van Allen EM;Hodis E;Jacobus S;Supko JG;Stewart M;Choueiri TK;Gandhi L;Cleary JM;Elfiky AA;Taplin ME;Stack EC;Signoretti S;Loda M;Shapiro GI;Sabatini DM;Lander ES;Gabriel SB;Kantoff PW;Garraway LA;Rosenberg JE
通讯作者：
Rosenberg JE